Pharmacotherapy of Cardiac Arrhythmias-Basic Science for Clinicians

被引:12
作者
Shu, Juan [1 ]
Zhou, Jun [2 ]
Patel, Chinmay [3 ,4 ]
Yan, Gan-Xin [1 ,3 ,4 ,5 ]
机构
[1] Xi An Jiao Tong Univ, Hosp 1, Xian 71006, Peoples R China
[2] Xi An Jiao Tong Univ, Sch Med, Dept Pharmacol, Xian 71006, Peoples R China
[3] Main Line Hlth Heart Ctr, Wynnewood, PA USA
[4] Lankenau Inst Med Res, Wynnewood, PA USA
[5] Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA
来源
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY | 2009年 / 32卷 / 11期
关键词
antiarrhythmic drugs; arrhythmias; atrial fibrillation; automaticity; reentry; triggered activity; TORSADE-DE-POINTES; ATRIAL-FIBRILLATION; CONTEMPORARY MANAGEMENT; VENTRICULAR-TACHYCARDIA; AMIODARONE; THERAPY; SOTALOL; FLECAINIDE; GUIDELINES; RHYTHM;
D O I
10.1111/j.1540-8159.2009.02526.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiac arrhythmias occur in approximately 5.3% of the population and contribute substantially to morbidity and mortality. Pharmacological therapy still remains the major approach in management of patients with nearly every form of cardiac arrhythmia. Effective and safe management of cardiac arrhythmias with antiarrhythmic drugs requires understanding of basic mechanisms for various cardiac arrhythmias, clinical diagnosis of an arrhythmia and identification of underlying cardiac diseases, pharmacokinetics, and antiarrhythmic properties of each individual antiarrhythmic drug. Most cardiac arrhythmias occur via one of the two mechanisms: abnormal impulse formation and reentry or both. Antiarrhythmic drugs primarily work via influencing cardiac automaticity or triggered activity or by their effects on effective refractoriness of cardiac cells. Proarrhythmic effects of antiarrhythmic drugs are also briefly discussed in this review article. (PACE 2009; 32: 1454-1465)
引用
收藏
页码:1454 / 1465
页数:12
相关论文
共 46 条
[1]  
[Anonymous], 1989, NEW ENGL J MED, V321, P406
[2]  
Antzelevitch C, 2008, HURSTS HEART, P913
[3]   beta(2)-Adrenergic receptor antagonists protect against ventricular fibrillation - In vivo and in vitro evidence for enhanced sensitivity to beta(2)-adrenergic stimulation in animals susceptible to sudden death [J].
Billman, GE ;
Castillo, LC ;
Hensley, J ;
Hohl, CM ;
Altschuld, RA .
CIRCULATION, 1997, 96 (06) :1914-1922
[4]  
Blomstrom-Lundqvist Carina, 2003, Journal of the American College of Cardiology, V42, P1493, DOI 10.1016/j.jacc.2003.08.013
[5]   Cardiac ionic currents and acute ischemia: From channels to arrhythmias [J].
Carmeliet, E .
PHYSIOLOGICAL REVIEWS, 1999, 79 (03) :917-1017
[6]   Mechanisms for the genesis of paroxysmal atrial fibrillation in the Wolff-Parkinson-White syndrome:: intrinsic atrial muscle vulnerability vs. electrophysiological properties of the accessory pathway [J].
Centurion, Osmar Antonio ;
Shimizu, Akihiko ;
Isomoto, Shojiro ;
Konoe, Atsushi .
EUROPACE, 2008, 10 (03) :292-300
[7]   Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia [J].
Clancy, CE ;
Rudy, Y .
NATURE, 1999, 400 (6744) :566-569
[8]   Comparison of β-blockers, amiodarone plus β-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators -: The optic study.: A randomized trial [J].
Connolly, SJ ;
Dorian, P ;
Roberts, RS ;
Gent, M ;
Bailin, S ;
Fain, ES ;
Thorpe, K ;
Champagne, J ;
Talajic, M ;
Coutu, B ;
Gronefeld, GC ;
Hohnloser, SH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (02) :165-171
[9]   New Horizons in antiarrhythmic therapy: Will novel agents overcome current deficits? [J].
Conway, Emily ;
Musco, Simone ;
Kowey, Peter R. .
AMERICAN JOURNAL OF CARDIOLOGY, 2008, 102 (6A) :12H-19H
[10]   SUCCESSFUL USE OF FLECAINIDE IN ATRIAL-FIBRILLATION WITH RAPID VENTRICULAR RATE IN THE WOLFF-PARKINSON-WHITE SYNDROME [J].
CRIJNS, HJGM ;
DENHEIJER, P ;
VANWIJK, LM ;
LIE, KI .
AMERICAN HEART JOURNAL, 1988, 115 (06) :1317-1321